Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of purified human CD34+ cells from patients treated with imatinib, and those from healthy donors

ABSTRACT: purified CD34+ cells from bone marrow of imatinib-treated patients were compared to those of healthy donors

ORGANISM(S): Homo sapiens

SUBMITTER: Benedikt Brors

PROVIDER: E-GEOD-1418 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.

Neumann F F Teutsch N N Kliszewski S S Bork S S Steidl U U Brors B B Schimkus N N Roes N N Germing U U Hildebrandt B B Royer-Pokora B B Eils R R Gattermann N N Haas R R Kronenwett R R

Leukemia 20050301 3

PMID: 15618956

Similar Datasets

Imatinib effects on CD34+ cells

Project description:purified CD34+ cells from bone marrow of imatinib-treated patients were compared to those of healthy donors Keywords = CML Keywords = CD34+ cells Keywords = imatinib Keywords: ordered

2004-05-24 | GSE1418 | GEO

RNA-Seq of CD34+ Bone Marrow Progenitors from Healthy Donors

Project description:To evaluate the transcriptome and splicing repertoire of bulk CD34+ sorted bone marrow progenitors we performed RNA-Seq. These data highlight an AML prognostic splicing signature that is present in healthy donors at equivalent frequencies to that found in AML bone marrow.

2019-08-22 | GSE118944 | GEO

RNA-Seq of CD34+ Bone Marrow Progenitors from Healthy Donors

Project description:RNA-Seq of CD34+ Bone Marrow Progenitors from Healthy Donors

| PRJNA487456 | ENA

Gene expression of CML CD34+ cells during Imatinib therapy

Project description:Imatinib has become the current standard therapy for patients with chronic myelogenous leukaemia (CML). For a better understanding of the Imatinib-related molecular effects in vivo, we assessed gene expression profiles of Philadelphia Chromosome positive (Ph+) CD34+ cells from peripheral blood of 6 patients with de novo CML in chronic phase. After 7 days of treatment with Imatinib the Ph+ CD34+ cells were reassessed to look for changes in the transcriptome. The expression level of 303 genes was significantly different comparing the transcriptome of the Ph+ CD34+ cells before and after 7 days of Imatinib therapy (183 down-regulated, 120 up-regulated, lower bound ≥1.2-fold). For a substantial number of genes governing cell cycle and DNA replication, the level of expression significantly decreased (CDC2, RRM2, PCNA, MCM4). On the other hand, therapy with Imatinib was associated with an increase of genes related to adhesive interactions, such as L-selectin or CD44. A group of 8 genes with differential expression levels were confirmed using a gene specific quantitative real-time PCR. Thus, during the first week of treatment, Imatinib is preferentially counteracting the bcr-abl induced effects related to a disturbed cell cycle and defective adhesion of leukemic Ph+ CD34+ cells.

2008-07-30 | GSE12211 | GEO

Expression profile of bone marrow HSCs from healthy donors

Project description:mRNA samples from bone marrow CD34+ cells (HSC) from healthy donors after co-culture assays (Control condition, with hMSCs and CD34+ cells from healthy donors; and AML condition, with hMSCs-AML and CD34+ cells from donors) were amplified, labeled and hybridized to the ClariomTM S Array human (Thermo Scientific, USA). Normalization and analysis of microarray data was performed using the Transcriptome Analysis Console (TAC) software (Affymetrix, USA).

2024-04-26 | GSE253556 | GEO

Transcription profiling of human CML CD34+ cells during Imatinib therapy

Project description:Imatinib has become the current standard therapy for patients with chronic myelogenous leukaemia (CML). For a better understanding of the Imatinib-related molecular effects in vivo, we assessed gene expression profiles of Philadelphia Chromosome positive (Ph+) CD34+ cells from peripheral blood of 6 patients with de novo CML in chronic phase. After 7 days of treatment with Imatinib the Ph+ CD34+ cells were reassessed to look for changes in the transcriptome. The expression level of 303 genes was significantly different comparing the transcriptome of the Ph+ CD34+ cells before and after 7 days of Imatinib therapy (183 down-regulated, 120 up-regulated, lower bound â¥1.2-fold). For a substantial number of genes governing cell cycle and DNA replication, the level of expression significantly decreased (CDC2, RRM2, PCNA, MCM4). On the other hand, therapy with Imatinib was associated with an increase of genes related to adhesive interactions, such as L-selectin or CD44. A group of 8 genes with differential expression levels were confirmed using a gene specific quantitative real-time PCR. Thus, during the first week of treatment, Imatinib is preferentially counteracting the bcr-abl induced effects related to a disturbed cell cycle and defective adhesion of leukemic Ph+ CD34+ cells. Experiment Overall Design: In total 6 patients with new diagnosis CML (Chronic Myelogenous Leukemia) in chronic phase are inculded in the study. The gene expression profiles of the CD34+ hematopoietic stem and progenitor cells from the patients before first treatment with Glivec (Imatinib) are compared to the gene expression profiles of the CD34+ hematopoietic stem and progenitor cells of the same patients after 7 days of treatment with 400 mg Glivec / day.

2008-10-21 | E-GEOD-12211 | biostudies-arrayexpress

Single cell transcriptome analysis of normal, Thalassemia and sickle cell donors' bone marrow CD34+ cells

Project description:4 normal, 3 thalassemia major and 5 sickle cell donors' bone marrow CD34+ cells were analyzed using 10X chromium platform and also Lineage depleted CD34+ cells from one normal sample

2019-10-01 | GSE133181 | GEO

Bulk RNA-seq of aplastic anemia (AA) and healthy donors

Project description:Bulk RNA-seq data of Lin-CD34+ hematopoietic stem and progenitor cells derived from bone marrow of healthy donors and untreated aplastic anemia patients

2021-03-31 | GSE165870 | GEO

CD34+ cells from mast cell leukemia and healthy bone marrow

Project description:In patients with mast cell leukemia, the CD34+ bone marrow fraction contains a subset of disease-initiating and propagating cells. The aim of this study was to compare the gene expression profile of these cells with that of CD34+ cells obtained from the bone marrow of healthy donors, in order to find aberrantly expressed genes and pathways.

2020-04-14 | GSE103223 | GEO

Gene expression data from CD34+ BMMCs/PBMCs from MPN patients vs. healthy controls

Project description:Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET) and seconday myelofibrosis (SMF), comprising post-ET-MF(pET-MF) and post-PV-MF(pPV-MF). In this dataset, we compare the gene expression data of bone marrow or peripheral blood mononuclear cells (BMMCs/PBMCs) of CD34+ cells from MPN patients and healthy donors.

2021-11-24 | GSE174060 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data